April 24th 2024
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.
Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status
May 18th 2022Patients with untreated, IGHV-mutated and -unmutated chronic lymphocytic leukemia experienced better overall survival and progression-free survival with ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab.
Introduction and CLL Background
May 16th 2022Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.
Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists
Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.
Use of Inotuzumab for ALL in the Frontline Setting
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
Poor 2-Year Overall Survival Observed Following HSCT in TP53-Mutant AML
April 29th 2022Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.
Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML
April 29th 2022JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Ivosidenib and Azacitidine Yield Significant Clinical Benefit Vs Placebo in IDH1-Mutant AML
April 21st 2022Patients with previously untreated IDH1-mutant acute myeloid leukemia experienced significant clinical benefit following treatment with ivosidenib and azacitidine compared with the placebo combination.
Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL Indications
April 18th 2022TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
FDA Places Partial Clinical Hold on Phase 1/2 Emavusertib Study in R/R AML, High-Risk MDS
April 6th 2022The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.